❌

Normal view

Received — 27 May 2026 ⏭ Nature Cancer

Copper depletion boosts CNS leukemia therapy by inhibiting nucleotide synthesis through impairment of mitochondrial complex IV activity

✇Nature Cancer
By: Alan Y. L. Wong · Jacob W. Myers · Gyan Prakash · Alice Ma · Jeannette R. Brook · Boryana Petrova · Baran Bulut · Ralph White III · Catherine Merz · Maeve de Souza · Adam G. Maynard · Peng Wang · Amy Yu · Nancy K. Pohl · Michal Weitman · Lewis B. Silverman · Kimberly Stegmaier · L. Stirling Churchman · Peter D. Cole · Donita C. Brady · Naama Kanarek
25 May 2026 at 08:00

Nature Cancer, Published online: 25 May 2026; doi:10.1038/s43018-026-01177-4

Wong et al. uncover a nutritional dependency for acute lymphoblastic leukemia cells that spread to the central nervous system and propose using copper restriction to impair leukemia progression by disrupting nucleotide synthesis through the inhibition of electron transport chain activity.

Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial

✇Nature Cancer
By: Kimberly J. Perez · Andressa Dias Costa · Alexander Jordan · Thomas B. Karasic · Dalia Elganainy · Suryun Kim · Chen Yuan · Dan Y. Gui · Runzi Tan · Sung Chul Hong · Xi Wang · Simona Cristea · Emma Coleman · Morgan Truitt · Tae Gyu Oh · Hui Zheng · C. Sloane Furniss · Lauren Brais · Alexandra Bird · Josh Remland · Vasilena Gocheva · Jennifer S. Thalappillil · Mark Anderson · James M. Cleary · Andrea Enzinger · Marios Giannakis · Kimmie Ng · Douglas A. Rubinson · Benjamin Schlechter · Rishi Surana · Harshabad Singh · Thomas Abrams · Ursina Teitelbaum · Natallia Izgur · Eliezer Allen · Peter S. Winter · Srivatsan Raghavan · Jen Jen Yeh · Daniel Von Hoff · Christopher Liddle · Michael Downes · Ronald M. Evans · Peter O’Dwyer · Andrew Aguirre · Jonathan A. Nowak · Brian M. Wolpin
25 May 2026 at 08:00

Nature Cancer, Published online: 25 May 2026; doi:10.1038/s43018-026-01165-8

In this phase 2 trial, Perez et al. reported the safety of the vitamin D receptor agonist paricalcitol with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma and the pharmacodynamic effects of paricalcitol in fibroblasts and immune cells.

Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases

✇Nature Cancer
By: Sophia Navarre · Maki N. Ishibashi · Achuth Nair · Ivan Reyes-Torres · Meriem Belabed · Laszlo Halasz · Matthew D. Park · Raphaël Mattiuz · Merouane Ounadjela · Gertrude Gunset · Jorge Mansilla-Soto · Judith Feucht · Annalisa Cabriolu · Jessica Le Berichel · Alexander Birbrair · Justin Eyquem · Brian D. Brown · Miriam Merad · Michel Sadelain · Jalal Ahmed
22 May 2026 at 08:00

Nature Cancer, Published online: 22 May 2026; doi:10.1038/s43018-026-01167-6

Ahmed and colleagues show that, by promoting ‘dressing’ of intact tumor target antigens onto dendritic cells, tumor irradiation enhances chimeric antigen receptor T cell persistence and efficacy in lung metastasis models.

Coupling dead cell recognition to Fcγ receptors augments anticancer immunity

✇Nature Cancer
By: Tomás Castro-Dopico · Cécile Piot · Michael D. Buck · Lucía Gandullo-Sánchez · Kok Haw Jonathan Lim · Gerone A. Gonzales · Nikita Rosendahl · Oliver Schulz · William Stainier · Brian Vash · Stephanie Maiocco · Conor M. Henry · Bruno Frederico · Sonia Lee · Andy Bo Zhang · Neil C. Rogers · Jayanta Bordoloi · Chloë Roustan · Svend Kjaer · Mohit Trikha · Hans Stauss · Ahmet Hazini · Kristen J. Radford · Zewen Kelvin Tuong · Johnathan Canton · Raj Mehta · Caetano Reis e Sousa
20 May 2026 at 08:00

Nature Cancer, Published online: 20 May 2026; doi:10.1038/s43018-026-01168-5

Castro-Dopico et al. report the design of reagents to bridge F-actin and Fcγ receptors, endowing a range of antigen-presenting cells with the ability to cross-present antigens from dead tumor cells and boosting antitumor immunity in preclinical models.

Targeting cysteinyl leukotriene receptor 1 reprograms tumor-promoting myelopoiesis and overcomes immune checkpoint therapy resistance

✇Nature Cancer
By: Hui Tang · Ping Xie · Jihae Ahn · Mi-Ran Choi · Jie Fan · Siqi Chen · Yi Zhang · Bin Zhang
19 May 2026 at 08:00

Nature Cancer, Published online: 19 May 2026; doi:10.1038/s43018-026-01174-7

Tang et al. identify cysteinyl leukotriene receptor 1 (CysLTR1) as a critical regulator of tumor-induced myelopoiesis, suggesting CysLTR1 targeting to sensitize tumors to immune checkpoint blockade.
  • ✇Nature Cancer
  • Immunological outcomes of a bespoke DNA cancer vaccine in glioblastoma
    Nature Cancer, Published online: 18 May 2026; doi:10.1038/s43018-026-01162-xWe report the results of a phase 1 clinical trial (NCT04015700) evaluating the safety and immunogenicity of GNOS-PV01, a personalized DNA cancer vaccine, in patients with MGMT-unmethylated glioblastoma, after surgery and radiotherapy. Immune responses were detected in all but one patient, who received immunosuppressive steroids. The 24-month overall survival was 33%, including one patient who was alive more than 48 month
     
  • 🏷️
  • ↗️

Immunological outcomes of a bespoke DNA cancer vaccine in glioblastoma

✇Nature Cancer
18 May 2026 at 08:00

Nature Cancer, Published online: 18 May 2026; doi:10.1038/s43018-026-01162-x

We report the results of a phase 1 clinical trial (NCT04015700) evaluating the safety and immunogenicity of GNOS-PV01, a personalized DNA cancer vaccine, in patients with MGMT-unmethylated glioblastoma, after surgery and radiotherapy. Immune responses were detected in all but one patient, who received immunosuppressive steroids. The 24-month overall survival was 33%, including one patient who was alive more than 48 months after diagnosis.

CD300ld on pathologically activated neutrophils promotes tumor immune suppression by binding phosphatidylserine on CD8<sup>+</sup> T cells

✇Nature Cancer
By: Chaoxiong Wang · Peixuan Zheng · Anhui Wang · Xinrui Fan · Tianxiang Li · Jingjing Hong · Runze Wang · Chunyan Zhang · Chaogui Luo · Weiwei Yang · Dong Gao · Adili Salai · Min Luo · Zhigang Lu · Dianfan Li · Moubin Lin · Jiayin Peng · Guohui Li · Shuo Han · Yun Zhao
15 May 2026 at 08:00

Nature Cancer, Published online: 15 May 2026; doi:10.1038/s43018-026-01169-4

Zhao and colleagues show that CD300ld, upregulated in pathologically activated neutrophils, mediates contact-dependent suppression of cytotoxic CD8+ T cells by binding to phosphatidylserine, inhibiting antitumor immune responses.

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study

✇Nature Cancer
By: Anuradha Jayaram · Memuna Rashid · Alison H. M. Reid · Francesco Orlando · Suparna Thakali · Leila Zakka · Miriam Goncalves · Jacqueline O’Dwyer · Constantine Alifrangis · Rob Jones · Elias Pintus · Sarah Needleman · Diletta Bianchini · Anna Wingate · Kenrick Ng · Mark Linch · Ursula McGovern · John Staffurth · Simon J. Crabb · Susannah Brock · Alison Birtle · Osvaldas Vainauskas · Gianmarco Leone · Millenn Chiwewe · Allan Hackshaw · Andre Lopes · Daniel Wetterskog · Francesca Demichelis · Gerhardt Attard
15 May 2026 at 08:00

Nature Cancer, Published online: 15 May 2026; doi:10.1038/s43018-026-01172-9

Jayaram et al. assessed the performance of the combination of circulating tumor DNA and serum prostate-specific antigen for dynamic monitoring of metastatic prostate cancer at first-line treatment in this prospective observational clinical trial.
Received — 4 April 2026 ⏭ Nature Cancer
  • ✇Nature Cancer
  • Harnessing foundation models for digital pathology without re-training Zhiping Xiao · Sheng Wang
    Nature Cancer, Published online: 03 April 2026; doi:10.1038/s43018-025-01108-9Applications of digital pathology in clinical oncology have largely depended on the requirement for labeled data and model re-training. A study now presents PRET, a training-free framework with robust performance for pan-cancer diagnosis that adapts pathology foundation models to diverse tasks at inference stage, from screening and subtyping tasks to segmentation and metastasis detection tasks.
     
  • 🏷️
  • ↗️

Harnessing foundation models for digital pathology without re-training

✇Nature Cancer
By: Zhiping Xiao · Sheng Wang
3 April 2026 at 08:00

Nature Cancer, Published online: 03 April 2026; doi:10.1038/s43018-025-01108-9

Applications of digital pathology in clinical oncology have largely depended on the requirement for labeled data and model re-training. A study now presents PRET, a training-free framework with robust performance for pan-cancer diagnosis that adapts pathology foundation models to diverse tasks at inference stage, from screening and subtyping tasks to segmentation and metastasis detection tasks.

A tumor-derived metabolite primes the leptomeningeal pre-metastatic niche

✇Nature Cancer
By: Shi Li · Cyrus M. Ghajar
3 April 2026 at 08:00

Nature Cancer, Published online: 03 April 2026; doi:10.1038/s43018-026-01138-x

Leptomeningeal metastases are a devastating complication of solid tumors; how this niche becomes pro-metastatic remains poorly understood. A study now reveals that tumor cells prime a pre-metastatic niche within the leptomeninges via exosome-derived 5-HIAA, triggering vascular leakiness and accumulation of disseminated tumor cells.

Leptomeningeal metastatic cancer cells induce a permissive choroid plexus vasculature through extracellular-vesicle-derived 5-HIAA signaling

✇Nature Cancer
By: Yang Huang · Yifan Hou · Jiahui Yang · Wanqi Yang · Hanxin Liu · Haibao Peng · Xiaohui Li · Jiaxu Zhao · Ye Zhang · Rui Zeng · Youming Zeng · Cheng Li · Qiangqiang Zhang · Yudan Chi
3 April 2026 at 08:00

Nature Cancer, Published online: 03 April 2026; doi:10.1038/s43018-026-01145-y

Huang, Hou, Yang et al. demonstrate that leptomeningeal metastatic cells favor the formation of a premetastatic niche by remodeling the choroid plexus vasculature through the serotonin metabolite 5-hydroxyindoleacetic acid, which signals into endothelial cells through the aryl hydrocarbon receptor.

PRET is a few-shot system for pan-cancer recognition without example training

✇Nature Cancer
By: Yi Li · Ziyu Ning · Tianqi Xiang · Qixiang Zhang · Zhihao Lin · Min Yi · Feiyan Feng · Baozhen Zeng · Xuexia Qian · Lu Sun · Jiace Qin · Ling Xiang · Chao Fan · Tian Qin · Qian Wang · Xiu-Wu Bian · Kun-Hsing Yu · Kang Zhang · Qingling Zhang · Xiaomeng Li
3 April 2026 at 08:00

Nature Cancer, Published online: 03 April 2026; doi:10.1038/s43018-026-01141-2

Li et al. present PRET, a few-shot system for pan-cancer detection not requiring model fine-tuning, validated it in multicenter datasets and found that it outperformed existing approaches across tasks and pathologists in lymph node metastasis detection.

Single-cell and spatial profiling in cancer biology and clinical oncology

✇Nature Cancer
By: Chris J. Frangieh · Joy Linyue Fan · Johannes C. Melms · Parin Shah · Elham Azizi · Benjamin Izar
3 April 2026 at 08:00

Nature Cancer, Published online: 03 April 2026; doi:10.1038/s43018-026-01142-1

Izar and colleagues review the insights into cancer biology gained via single-cell analyses and spatial profiling and overview the challenges and opportunities associated with the implementation of these approaches to guide clinical discovery.
Received — 2 April 2026 ⏭ Nature Cancer

Decoding pediatric brain tumors via CSF-derived methylomes

✇Nature Cancer
By: Camila S. Fang · Alexandra M. Miller
30 March 2026 at 08:00

Nature Cancer, Published online: 30 March 2026; doi:10.1038/s43018-026-01139-w

Cerebrospinal fluid (CSF)-derived cell-free DNA holds promise for CNS tumors, but its limited yield poses challenges. A study now presents M-PACT, a framework that uses sub-nanogram CSF-derived cell-free DNA methylomes for tumor classification, paving the way for minimally invasive diagnosis of pediatric brain tumors.
Received — 26 March 2026 ⏭ Nature Cancer

Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphoma

✇Nature Cancer
By: Felix Czernilofsky · Anna Mathioudaki · Lea Jopp-Saile · Raphael Lutz · Dominik Vonficht · Xi Wang · Christina Schniederjohann · Harald Voehringer · Tobias Roider · Marc-Andrea Baertsch · Claus Rodemer · Henry Löffler-Wirth · Michael Grau · Donnacha Fitzgerald · Johannes Mammen · Jan Kosla · Nora Liebers · Peter-Martin Bruch · Diana Ordoñez-Rueda · Alexander Brobeil · Gunhild Mechtersheimer · Caroline Pabst · Carsten Müller-Tidow · Andreas Trumpp · Marc Seifert · Frank Neumann · Mathias Heikenwälder · Vladimir Benes · Wolfgang Huber · Jörg Distler · Georg Lenz · Hans Binder · Reiner Siebert · Garry P. Nolan · Moritz Gerstung · Judith B. Zaugg · Daniel Hübschmann · Simon Haas · Sascha Dietrich
25 March 2026 at 08:00

Nature Cancer, Published online: 25 March 2026; doi:10.1038/s43018-026-01136-z

Czernilofsky et al. identified factors that reprogram stromal cells into an inflammatory, dysfunctional state, leading to the structural disorganization of lymph nodes in B cell lymphoma at single-cell and spatial resolutions.

Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study results

✇Nature Cancer
By: Rashmi K. Murthy · Barbara J. O’Brien · Donald A. Berry · Akshara Singareeka-Raghavendra · Maria Gule Monroe · Jason Johnson · Jason White · Jill Schwartz-Gomez · Ariel Topletz-Erickson · Mina Lobbous · Kristen Riley · Michelle Melisko · Aki Morikawa · Sherise D. Ferguson · John F. de Groot · Ian E. Krop · Vicente Valero · Mothaffar F. Rimawi · Antonio C. Wolff · Debu Tripathy · Nancy U. Lin · Erica M. Stringer-Reasor
18 March 2026 at 08:00

Nature Cancer, Published online: 18 March 2026; doi:10.1038/s43018-026-01120-7

Murthy and colleagues discussed recent research on the effect of a tucanitib–trastuzumab–capecitabine regimen in patients with HER2+ breast cancer and leptomeningeal metastasis.
Received — 14 March 2026 ⏭ Nature Cancer
  • ✇Nature Cancer
  • A functional map of m<sup>6</sup>A sites in cancer Yalong Wang · Han Xu
    Nature Cancer, Published online: 13 March 2026; doi:10.1038/s43018-026-01137-yRNA N6-methyladenosine (m6A) is the most abundant internal RNA modification, yet its functional landscape in cancer remains poorly defined. A study now introduces a METTL3-based RNA base-editing screen that maps functional m6A sites and reveals m6A-dependent translational activation of the tumor suppressor CHD9 in prostate cancer and beyond.
     
  • 🏷️
  • ↗️

A functional map of m<sup>6</sup>A sites in cancer

✇Nature Cancer
By: Yalong Wang · Han Xu
13 March 2026 at 08:00

Nature Cancer, Published online: 13 March 2026; doi:10.1038/s43018-026-01137-y

RNA N6-methyladenosine (m6A) is the most abundant internal RNA modification, yet its functional landscape in cancer remains poorly defined. A study now introduces a METTL3-based RNA base-editing screen that maps functional m6A sites and reveals m6A-dependent translational activation of the tumor suppressor CHD9 in prostate cancer and beyond.

The genomic model P-CARE enables precision prostate cancer screening in a national healthcare system

✇Nature Cancer
13 March 2026 at 08:00

Nature Cancer, Published online: 13 March 2026; doi:10.1038/s43018-025-01111-0

We developed and clinically implemented the genomic prostate cancer risk prediction model P-CARE that identifies men at a high or low risk of prostate cancer. P-CARE enabled the design and initiation of a precision screening trial across the national healthcare system in which it was developed.
  • ✇Nature Cancer
  • AI for breast cancer screening Allan Hackshaw · Rosalind Given-Wilson
    Nature Cancer, Published online: 10 March 2026; doi:10.1038/s43018-025-01109-8Whether support from artificial intelligence (AI) models improves breast screening is a topic of research in national cancer screening programmes and clinical oncology. Three studies now show that AI tools can assist radiologists with evaluating mammograms, substantially reducing workloads and possibly improving screening performance.
     
  • 🏷️
  • ↗️

AI for breast cancer screening

✇Nature Cancer
By: Allan Hackshaw · Rosalind Given-Wilson
10 March 2026 at 08:00

Nature Cancer, Published online: 10 March 2026; doi:10.1038/s43018-025-01109-8

Whether support from artificial intelligence (AI) models improves breast screening is a topic of research in national cancer screening programmes and clinical oncology. Three studies now show that AI tools can assist radiologists with evaluating mammograms, substantially reducing workloads and possibly improving screening performance.

Diagnostic accuracy, fairness and clinical implementation of AI for breast cancer screening: results of multicenter retrospective and prospective technical feasibility studies

✇Nature Cancer
By: Christopher J. Kelly · Marc Wilson · Lucy M. Warren · Richard Sidebottom · Mark Halling-Brown · Lin Yang · Megumi Morigami · Jenny Venton · Reena Chopra · Jane Chang · Jonathan Dixon · Fiona J. Gilbert · Daniel I. Golden · Elzbieta Gruzewska · Lesley Honeyfield · Amandeep Hujan · Delara Khodabakhshi · Emma Lewis · Namrata Malhotra · Rachita Mallya · Della Ogunleye · Charlotte Purdy · Rory Sayres · Marcin Sieniek · Tsvetina Stoycheva · Aminata Sy · Susan Thomas · Dominic Ward · Lihong Xi · Shawn Xu · Shravya Shetty · Ara Darzi · Kenneth Young · Hema Purushothaman · Lisanne Khoo · Mamatha Reddy · Hutan Ashrafian · Deborah Cunningham
10 March 2026 at 08:00

Nature Cancer, Published online: 10 March 2026; doi:10.1038/s43018-026-01127-0

Kelly et al. assessed an artificial intelligence system for breast cancer screening in retrospective datasets, followed by prospective feasibility evaluation, and report its accuracy, fairness and clinical implementation in multiple workflow settings.
❌